The CRISPR IP landscape can often seem like a labyrinth. ARK aims to summarize the key CRISPR stakeholders and collaborations, including: i) licenses from patent holders, ii) sub-licenses from surrogates to collaborators, iii) areas of CRISPR research, and iv) exclusive vs. non-exclusive licenses.
ARK believes the IP battle will result in cross-licensing agreements and the global proliferation of CRISPR technology. While it may be years until we have a resolution, the benefits of CRISPR are already tangible. To read the full research report, please fill out the form and download ARK's white paper.
You also may be interested in our white paper: